DWP16001 is one of 93 small molecule programs targeting Diabetic Nephropathy. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
885 competitors in Type 2 Diabetes
Byetta
DWP16001
NOVOLIN R
Glargine
Pravachol
Sulfonylureas
GLP-1
Blank Control
Henagliflozin
Antiplatelet Drug
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details